Mary Elizabeth "Betz" Halloran (born 1951)

SUMMER INTERN POSTER SESSION AUGUST 11, 2017http://www.cidid.org/gallery img-2379.jpgimg-2379-crop.jpg

Wikipedia 🌐 Betz Halloran 

Saved wikipedia (April 4, 2023) for "Betz Halloran"

https://en.wikipedia.org/wiki/Betz_Halloran 

2023-04-04-wikipedia-betz-halloran.pdf

Mary Elizabeth (Betz) Halloran is an American biostatistician who works as a professor of biostatistics, professor of epidemiology, and adjunct professor of applied mathematics at the University of Washington.[1]

Education and career

Halloran studied physics and philosophy of mathematics for two years as an undergraduate at Case Western Reserve University, from 1968 to 1970,[2] before leaving school to join the counterculture movement in San Francisco.[3] Deciding to study medicine, she returned to school,[3] completing a bachelor's degree in general science at the University of Oregon in 1972.[2]

She traveled to Berlin to continue her studies at the Max Planck Institute for Molecular Genetics and the Free University of Berlin from 1973 to 1975,[2][3] studied medicine at the University of Southampton in England in 1981, and completed an M.D. at the Free University of Berlin in 1983.[2] Her goal at that time was to practice medicine in the developing world,[3] so she continued to study tropical diseases at the Bernhard Nocht Institute for Tropical Medicine in Hamburg in 1984, and then earned a master of public health degree from Harvard University in 1985.[2] In that program, she rekindled her interest in mathematical modeling,[3] and she stayed at Harvard as a graduate student, earning a D.Sc. in population sciences from Harvard in 1989.[2][4]

After postdoctoral research at Princeton University and Imperial College London, she joined Emory University as an assistant professor of epidemiology and biostatistics in 1989, and was promoted to full professor in 1998. At Emory, she directed the Center for AIDS Research from 2002 to 2005, and the Center for Highthroughput Experimental Design and Analysis from 2004 to 2005. She moved to the University of Washington in 2005. In 2009, she founded the Summer Institute in Statistics and Modeling in Infectious Diseases at the University of Washington, and continues to serve as its director.[2]

Research

Halloran studies causal inference and the biostatistics of infectious diseases.[3] She is a long-term collaborator with University of Florida researcher Ira Longini, with whom she studies the spread of influenza.[5][6] She has also been quoted as an expert on the mortality rates of other diseases such as ebola and cholera, and the factors influencing those rates.[7]

With Longini and Claudio J. Struchiner, she is a co-author of the book Design and Analysis of Vaccine Studies (Springer, 2009).[8][9][10]

Awards and honors

In 1996, Halloran was elected as a fellow of the American Statistical Association, in 1997 she became a fellow of the Royal Statistical Society, and in 2009 she became a fellow of the American Association for the Advancement of Science.[2][11]

In 2005 and 2006 she held the Dr. Ross Prentice Professorship of Biostatistics at the University of Washington.[2]

References


https://www.ancestry.com/discoveryui-content/view/318763675:62209?tid=&pid=&queryId=238be4ead6996cbfe67b4c16865faaaa&_phsrc=kyz228&_phstart=successSource 

Elizabeth E Halloran



Detail Source

Name

Elizabeth E Halloran

[Elizabeth Mallorao]

[Elizabeth M Halloran]

[Elizabeth M Hollaran]

[M E Halloran]

[M E Hollaran]

Birth Date

Aug 1951

Residence Date

1989-2005

Address

1036 Rosedale Rd Ne

Residence

Atlanta, Georgia, USA

Postal Code

30306

Second Residence Date

2005-2020

Second Address

52 Skyline Cir

Second Residence

Santa Barbara, California, USA

Second Postal Code

93109

Third Residence Date

2007-2020

Third Address

5745 65th Ave Ne

Third Residence

Seattle, Washington, USA

Third Postal Code

98105

Fourth Residence Date

2006-2015

Fourth Address

1100 Fairview Ave N

Fourth Residence

Seattle, Washington, USA

Fourth Postal Code

98109



https://www.whitepages.com/name/Mary-Elizabeth-Halloran/Atlanta-GA/Pw9YmwvZd9R

2023-04-05-whitepages-com-mary-elizabeth-halloran-atlanta-ga-1.pdf

Mary Elizabeth Halloran

(Elizabeth E Halloran, Elizabeth Mallorao)


BIRTHDATE

8/19/1951 (71yrs)

LOCATION

Atlanta, GA


MARY'S RELATIVES (3)


Gavin Banks Halloran

Age 40s

Atlanta, GA

Patricia Idele Halloran

Age 60s

Santa Barbara, CA

Michael Scott Halloran

Age 70s

Evanston, IL



Resume/CV - 2010

Saved as : [HL009Q][GDrive

M. ELIZABETH HALLORANCurriculum VitaeDegrees1989 DSc Population Sciences, Harvard School of Public Health, Boston, MAConcentration: Human Ecology and Population Dynamics of Infectious Disease1985 MPH Tropical Public Health, Harvard School of Public Health, Boston, MA1983 MD Freie Universitat Berlin, West Berlin, Germany, licensure in Germany 19831972 BSc General Science, University of Oregon, Eugene, OregonFaculty Positions (primary)1/06{present Full Member Program in Biostatistics and BiomathematicsFred Hutchinson Cancer Research Center, Seattle1/06{present Professor Department of Biostatistics, School of PublicHealth, University of Washington9/98{12/05 Professor Department of Biostatistics, Rollins School of9/93{8/98 Associate Professor Public Health, Emory University9/90{8/93 Assistant Professor Division of Biostatistics,School of Public Health, Emory University12/89{8/90 Assistant Professor Department of Epidemiology and BiostatisticsSchool of Medicine, Emory UniversityFaculty Positions (secondary) and Responsibilities6/09{present Director and Founder, Summer Institute in Statistics and Modeling in InfectiousDiseases, Department of Biostatistcs, University of Washington9/05{12/05 Director, NIH/NIGMS Training Grant in Biostatisitics in Genetics,Immunology, and Neuroimaging (BGIN), Emory2/04{12/05 Director, Center for Highthroughput Experimental Design and Analysis (CHEDA), Emory9/02{12/05 Director, Center for AIDS Research, Biostatistics Core, Emory9/92{8/03 Director, NIH Statistical and Clinical Research Training Grant in AIDS, Emory9/96{12/05 Faculty, Population Biology, Ecology, and Evolution (PBEE) PhD Program,Graduate Division of Biological and Biomedical Sciences, Emory6/94{12/05 Secondary appointment Department of Epidemiology, Emory9/92{12/05 Secondary appointment Department of Biology, Emory CollegeVisiting situationsWinter 1995 Visiting Associate Professor University of Minnesota, BiostatisticsSpring 1995 Visiting Associate Professor Carnegie Mellon Univeristy, StatisticsSummer 1993, 94, 95, 99 Visiting Scholar Stanford University, StatisticsSummer 2003 Visiting Faculty Los Alamos National Laboratories, StatisticsWinter, Spring 2005 Visiting Faculty UC Santa Barbara, StatisticsPostdoctoral Education and Positions1989 Research Associate, Department of Biology, Princeton University, based at theDepartment of Pure and Applied Biology, Imperial College, University of London.1Faculty Advisor: Robert M. May.1985-86 Research Fellow, Department of Tropical Public Health, Harvard School ofPublic Health, Boston, MA. Faculty Advisor: Andrew Spielman.1984 Diploma in tropical medicine and parasitic diseasesBernard-Nocht Institute of Tropical Medicine, Hamburg, Germany1982-83 Medical Internship, City Hospital of Neukolln, Berlin, GermanyOther education1993{94 Graduate Student, Department of Mathematics, Georgia Institute of Technology, Atlanta, GA1981 Clinical electives: University of Southampton, Southampton, United Kingdom,orthopedics, neurology, neurosurgery1973-75 Graduate student, Max-Planck Institute for Molecular Genetics, Berlin, Germany1974-75 Vordiplom examination in biology: emphasis on plant physiology,Freie Universitat Berlin, Berlin, Germany1968-70 Case Western Reserve University, Cleveland, Ohio, Majors: physics, philosophy of mathematics1968 Harvard University Summer School, Boston, MA, abstract algebra and calculusOther Research Experience1989-90 Collaborator, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, RockefellerFoundation-funded project on modeling of AIDS vaccines at the cellular level1987 Epidemiologist, Theobald Smith Institute, Massachusetts State Laboratories, Boston, MA,formulation of a protocol for the National Seroprevalence Study of HIV Infectionin Childbearing Women1986-87 Co-organizer, comparative study of health e ects of the war in Nicaragua in collaborationwith people from Harvard School of Public Health, and the Schools of Public Healthand Medicine in Managua, Nicaragua1983-84 Medical research associate, City Hospital of Neukolln, West Berlin, study of ahypo-allergenic oral formula to prevent chronic diarrhea in infants with acute diarrhea1971-72 University of Oregon, Institute of Molecular Biology, Eugene, Oregon, student assistantin DNA recombination studies using   phage.Honors and Awards2009 Fellow, American Association for the Advancement of Science2006-2007 Dr. Ross Prentice Professor of Biostatistics, University of Washington2002 40th Don W. Gudakunst Memorial Lecture, Department of Epidemiology,University of Michigan1996 Fellow, American Statistical Association1997 Fellow, Royal Statistical Society9/86-6/87 Graduate Associate, Takemi Program of International Health, HarvardSchool of Public HealthLanguage FacilityEnglish (native), German (uent), Spanish (struggling), French, Portuguese (scienti c reading)2Memberships1990{ American Association for the Advancement of Science1993{2002 American Society of Tropical Medicine and Hygiene1990{ American Statistical Association1990{ Biometric Society1994{ Institute of Mathematical Statistics1989{2009 Society for Epidemiologic Research1989{2004 Society for Vector EcologyEditorial service2009{present Editorial Board, Statistical Communications in Infectious Diseases2008{present Editorial Board, Epidemics2004{present Associate Editor, Biometrics2002{2009 Associate Editor, American Journal of Epidemiology (also 1991{97)1994{2005 Editorial Board, Statistics in Medicine1998{2003 Associate Editor, Journal of the American Statistical Association,Applications and Case Studies1993{98 Editorial Board, EpidemiologyService to professional associations2003{2005 Member, Selection Committee, Excellence in Statistical Reporting Award,American Statistical Association2004{2006 Member, ( 2006 Chair) Fellow Selection Committee, American Statistical Association1998{2003 Board of Trustees, National Institute of Statistical Sciences1991{93 Member, Core exam writing group, American Board of Preventive Medicine.1994{95 Program Chair, Section on Epidemiology, American Statistical AssociationTechnical assistance and consulting2008{present Merck Advisory Panel for Second Generation HPV Vaccines2004{2008 NIH Study Section for Biostatistics Methods and Research Design2007{2008 WHO Quiver Committee2008 NIH Reviewer, Young Innovator Awards2007 NIH Panel for Interviewing the Pioneer Award Finalists.2006 Merck, consultation on HIV vaccines, October 10, 2006.2005 National Centers for Disease Control and Prevention, June 21, 2005, Plan for pandemic inuenza.2005 Global Health Security Action Group (G7 plus Mexico) (Inuenza Modeling Workshopand Tabletop Exercise) London, May 31-June 3, 2005, under auspices of DHHS.2005 Texas Inuenza Vaccine Study Investigators' Meeting, Temple, Texas, May 24-25, 2005.2004-2005 Riverside County Health Department Modeling Workshop for Public Health Practitioners,Palm Springs, California, March 2005, Planning Committee and two talks.2004 FDA on improving FDA's approach to clinical trials and vaccines, October 2004, invited talk.2004 Merck, consultation on design of vaccine studies, October 4, 2004.2004 Department of Health and Human Services, August 2004, Planning for pandemic inuenza.2002{2004 Working Group on Smallpox Modeling of the Secretary's Committee on Public HealthPreparedness.32004 WHO, External Review Group, Estimating Measles Mortality, January, 20041999{2003 Data Safety and Monitoring Board, Vaxgen International and Domestic HIV VaccineTrials, Thailand and USA.1998{2002 Aviron, consulting, inuenza vaccine community trials1999{2002 Merck Research Laboratories, consulting2001 NIH R01 external reviewer, SNEM-5 Study section, December, 20012001 NIH/NCI, Chair of P01 Site visit and review, January, 20012001 NIH/NCI, Ad hoc Member, P01 Parent Committee, March, 20012001 EPA, Scienti c Advisory Panel, Probabilistic Models and Methodologies:Advancing the Ecological Risk Assessment Process in the EPA O ce ofPesticide Programs, March 13-16, 20012001 NSF review of Technology Center proposal1998-2004 External NSF grant review, one or two per year1992{99 NIH Biostatistics Special Study Section (then SNEM-5) (15 times 1992{99, chair  ve times)1995{97 NSF Institute of Mathematics and its Applications, Organizing Committee forSummer 1997 Workshop on Statistics in the Health Sciences.1994{95 National Academy of Science, Institute of Medicine, Committee on Vaccine Development:Establishing Priorities for the U.S. for the 21st Century1995 NSF, Division of Mathematical Sciences, Review PanelCareer Advancement Awards and Research Planning Grants1994{98 PDU/TDR/WHO Transmission-blocking Malaria Vaccine Task Force1994 NIH Review: HIV Vaccine Preparedness Study and Phase III Trial Sites (6/94)1995 NIH P01 Review Group with reverse site visit, National Cancer Institute1997 NIH P01 Initial Review Group with site visit, National Cancer Institute (5/97)1993 CDC Expert panel discussion on varicella vaccines, January 12, 1993.1991 Consultant, Evaluating the Schools of Public Health in Bolivia, March 1-16, 1991.1990 Consultant, Seminar on Methods for Study Designs for Malaria Vaccines,Instituto de Inmunologia, Bogota, Colombia, July 16-19, 1990.1989 Participant, First International Meeting of Unesco Project to ImprovePrimary School Performance, Nutrition and Health Stockholm, Sweden, April 3-5.University of Washington coursesAnalytic Methods for Infectious Disease, Winter 2007, Winter 2009Emory University coursesCausal Inference WS 2005-06Bayes and empirical Bayes methods, SS 1996, WS 1998-99, WS 2000-01, SS 2003.Analysis of microarray data, SS 2002, WS 2003.Missing and mismeasured data, WS 1996-97, SS 2000.Statistical computing, WS 1997-98, SS 2000.Theory of survival analysis, including counting processes, SS 1992, SS 1994.Generalized Linear Models, SS 2001.Introduction to analytic methods for infectious disease interventions, SS 1993.Analytic methods for infectious disease interventions, SS 1990-91, SS 1992-93, WS 1995-96, WS 1997-98.Population Biology and Dynamics of Disease, WS 1993-94.Advanced Seminar in Biometry, WS 1990-91, SS 1993.4Epidemiology of AIDS: methodological issues, SS 1989-90, WS 1991-92.PhD Research Seminar, WS 1995-96, WS 1996-97, WS 1998-99.Harvard University coursesSS 1989 Teaching Fellow (course coordinator), Biology, Epidemiology, Economics and Policyof Malaria (BEEP), Department of Tropical Public Health, School of Public HealthWS 1988 Population Dynamics of Infectious Diseases in Humans, Biology Department,Faculty of Arts and Sciences1986-87 Population Dynamics of Infectious Diseases in Humans, full year undergraduate seminar,Biology Department, Faculty of Arts and Sciences.Short courses and tutorials1992 New England Epidemiology Summer Program, Boston MA, July 12-31,Concepts in Infectious Disease Epidemiology1992 University of S~ao Paulo, Brazil, August 3-6, Concepts in Infectious Disease Epidemiology1997 Chiron Corporation, Emeryville, CA, December 15-16,Design and Analysis of Vaccine Studies1998 Bristol Myers Squibb, Connecticut, April 24,Design and Analysis of Vaccine Studies, Causal Inference2000 Research Methods on Vaccines and Immunization in Public Health,Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, December 18-22.2006 Analytic Methods for Infectious Diseases, ENAR Biometrics Meeting, Tampa, FL, March, 20062007 Analytic Methods for Infectious Diseases, ENAR Biometrics Meeting, Atlanta GA, March, 2007Other  Proposer and Organizer,Workshop on Analysis of Infectious Disease Data, Mathematisches Forschungsinstitutin Oberwolfach, Germany, November 1-7, 2009.Doctoral dissertations directedEmory:1992 P. Rhodes, PhD Biostatistics1992 O. Devine, PhD Biostatistics1995 M. Kolzcak, PhD Biostatistics1997 D. Dunson, PhD Biostatistics1998 G.T. Golm, PhD Biostatistics2001 K. T.Cuenco, PhD Epidemiology2003 Haitao Chu, PhD Biostatistics2007 Haiyan Wu, PhD Biostatistics(2011) Nicole Basta, PhD EpidemiologyDoctoral committeesEmory:1990 V.J.C. Suman, PhD Biostatistics.1990 W.S. Clark, PhD Biostatistics1994 J. Bertolli, PhD Epidemiology (UCLA).51995 D.J. Mosur, PhD Epidemiology.1997 L.K. Durham, PhD Biostatistics.1997 M.R. Sternberg, PhD Biostatistics1999 B. Viswanathan, PhD Biostatistics2000 M. Hudgens, PhD Biostatistics2000 D. Price, PhD Biostatistics2002 E. Hill, PhD Biostatistics2004 Y. Yang, PhD Biostatistics2006 E. Tassone, PhD BiostatisticsU Washington:2008 JoAnna Scott, PhD Biostatistics(2010) Jonathan Sugimoto, PhD Epidemiology(2010) Laura Matrajt, PhD, Applied Mathematics(2010) Gail Potter, PhD, StatisticsMasters' theses directed1992 N. Wahlay, general MPH.1999 D. Cowart, biostatistics MSPH.Faculty sponsor1992{96 F. Powell, PhD student Biostatistics, recipient of an NIH minority predoctoral fellowshipPeer{reviewed publications1. Russo VEA, Gallori E, and Halloran ME. (1977) Ethylene is Involved in the Autochemotropism ofPhycomyces. Planta 134:61-67.2. Struchiner CJ, Halloran ME, and Spielman A. (1989) Modeling Malaria Vaccines I: New Uses for OldIdeas. Math Biosc, 94:87-113.3. Halloran ME, Struchiner CJ, and Spielman A. (1989) Modeling Malaria Vaccines II: Population E ectsof Stage-speci c Malaria Vaccines Dependent on Natural Boosting. Math Biosc, 94:115-149.4. Nicaragua Health Study Collaborative at Harvard, and CEIS, and UNAN. (1989) Health E ects ofthe War in Nicaragua in Two Communities. Am J Pub Health, 79:424-430.5. Halloran ME, Bundy DAP, and Pollitt E. (1989) Infectious Disease and the Unesco Basic EducationInitiative. Parasitology Today, 5:359-362.6. Struchiner CJ, Halloran ME, Robins JM, Spielman A. (1990) The Behavior of Common Measuresof Association Used to Assess a Vaccination Program under Complex Transmission Patterns - AComputer Simulation Study of Malaria Vaccines. Int J Epidemiol, 19:187-196.7. Longini IM, Haber MJ, Halloran, ME. (1990) Efectos directos e indirectos de las vacunas: un anotaci onsobre la estimaci on de la e cacia vacunal a partir de brotes por agentes de infecciones agudas comosarampi on. Bol Med Hosp Infant Mex, 47:516-520.68. Halloran ME, Haber MJ, Longini IM, Struchiner CJ. (1991) Direct and Indirect E ects in VaccineE cacy and E ectiveness. Am J Epidemiol, 133:323-331.9. Haber MJ, Longini IM, Halloran, ME. (1991) Measures of the E ects of Vaccination in a RandomlyMixing Population. Int J Epidemiol, 20:300-310.10. Haber MJ, Longini IM, Halloran, ME. (1991) Estimation of Vaccine E cacy in Outbreaks of AcuteInfectious Diseases. Statistics in Medicine, 10:1573-1584.11. Halloran ME and Struchiner CJ. (1991) Study Designs for Dependent Happenings. Epidemiology,2:331-338.12. Struchiner CJ and Halloran ME. (1992) Models of AIDS Vaccines: The Cellular Level. Memorias deInstituto Oswaldo Cruz, Rio de Janeiro, 87:103-113.13. Halloran ME, Haber MJ, and Longini, IM. (1992) Interpretation and Estimation of Vaccine E cacyunder Heterogeneity. Am J Epidemiol, 136:328-343.14. Halloran ME and Struchiner CJ. (1992) Modeling transmission dynamics of stage-speci c malariavaccines. Parasitology Today, 8:77-85.15. Halloran ME. (1992) Persistence, Drugs, and Rock'n'Roll. Trends in Ecology and Evolution, 7:212-214.16. Longini IM, Halloran ME, Haber MJ, Chen, RT. (1993) Measuring Vaccine E cacy from Epidemics ofAcute Infectious Agents: Study Designs and Estimation Methods. Statistics in Medicine, 12:249-263.17. Brunet R, Struchiner CJ, and Halloran ME (1993) On the distribution of vaccine protection underheterogeneous response. Math Biosc, 116:111-125.18. Longini IM, Halloran ME, and Haber MJ (1993) Estimation of vaccine e cacy from epidemics of acuteinfectious agents under vaccine-related heterogeneity. Math Biosc, 117:271{281.19. Halloran, ME. (1993) Salmonella enteritidis infection in France and the United States: causes versuscausal models. American Journal of Public Health 83:1667-1669.20. Lieu TA, Cochi SL, Black S, Halloran ME, Shine eld HR, Holmes SR, Wharton M, and WashingtonAE. (1994) Cost-e ectiveness of a routine varicella vaccination program for US children. Journal ofthe American Medical Association, 271:375{381.21. Halloran, ME. (1994) Mycobacterium tuberculosis: just desserts for an ungrateful luncheon guest.Trends in Ecology and Evolution 9:72{74.22. Halloran ME, Longini IM, Struchiner CJ, Haber MJ, Brunet R. (1994) Exposure e cacy and changein contact rates in evaluating HIV vaccines in the  eld, Statistics in Medicine, 13:357-377.23. Halloran ME, Struchiner CJ, and Watelet, L. (1994) Epidemiologic e ects of vaccines with complexdirect e ects in an age-structured population, Math Biosciences 121:193{225.24. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. (1994) Epidemiologic and morbidity e ectsof routine varicella immunization of preschool children in the United States, American Journal ofEpidemiology, 140:81{104.725. Devine OJ, Louis TA, Halloran ME. (1994) Empirical Bayes methods for stabilizing incidence ratesbefore mapping, Epidemiology 5:622-630.26. Longini, IM, Halloran, ME, Haber MJ. (1995) Some current trends in estimating vaccine e cacy, inEpidemic Models: Their Structure and Relation to Data, pp. 394{403, ed. D. Mollison, CambridgeUniversity Press, Cambridge.27. Halloran ME, Longini IM, Struchiner CJ, Haber MJ. (1995) Feasibility of prophylactic HIV vaccinetrials: some statistical issues. in Models for Infectious Human Diseases, pp. 76{82, ed. V.S. Ishamand G. Medley, Cambridge University Press, Cambridge.28. Devine OJ, Louis TA, Halloran ME. (1994) Empirical Bayes estimators for spatially correlated incidencerates, Environmetrics, 5:381-398.29. Haber M, Halloran ME, Longini IM, Watelet L. (1995) Estimation of vaccine e cacy in non-randomlymixing populations. Biometrical Journal 37:1, 25{38.30. Halloran ME and Struchiner CJ. (1995) Causal inference for infectious diseases, Epidemiology, 6:142{151.31. Struchiner CJ, Halloran ME, Brunet R, Ribeiro JMC, Massad E. (1995) Malaria vaccines: lessonsfrom the  eld. Cadernos do Sa ude P ublica, 10(supplement 2):310-326.32. Longini IM and Halloran ME. (1995) AIDS: Modeling Epidemic Control. letter to Science 267:1250-1251.33. Haber MJ, Orenstein WA, Halloran, ME, Longini IM, and Watelet, L. (1995) The e ect of diseaseprior to an outbreak on estimates of vaccine e cacy, American Journal of Epidemiology, 141:980{990.34. Norohna, CP, Struchiner CJ, Halloran ME. (1995) Assessment of the direct e ectiveness of BCmeningococcal vaccine in Rio de Janeiro, Brazil: a case-control study, International Journal of Epidemiology,24(5):1050-1057.35. Haber MJ, Watelet L, and Halloran, ME. (1995) On individual and population e ectiveness of vaccination.Int J Epidemiol. 24:1249{1260.36. Struchiner CJ, Brunet R, Halloran ME, Massad E, Azevedo-Neto RS. (1995) On the use of state-spacemodels for the evaluation of health interventions. Journal of Biological Systems. 3:851{865.37. Longini IM and Halloran ME. (1996) A frailty mixture model for estimating vaccine e cacy. AppliedStatistics, 45:165{173.38. Devine OJ, Louis TA, Halloran ME. (1996) Identifying areas with high rates in mapping using empiricalBayes methods Geographic Analysis, 28: 187{199.39. Antia R. and Halloran ME. (1996) Recent developments in theories of pathogenesis of AIDS. Trendsin Microbiology, 4:282{285.40. Halloran, ME, Longini, IM and Struchiner, CJ. (1996) Estimability and interpretation of vaccinee cacy using frailty mixing models. American Journal of Epidemiology, 144:83{97.841. Efron B, Halloran ME, and Holmes, S. (1996) Bootstrap con dence intervals for phylogenetic trees,Proceedings of the National Academy of Sciences, 93:7085{7090.42. Mosure DJ, Berman S, Kleinbaum D, Halloran ME. (1996) Predictors of Chlamydia trachomatis infectionamong female adolescents: a longitudinal analysis, American Journal of Epidemiology, 144:997{1003.43. Halloran, ME. (1996) Evaluating HIV vaccines: discussion. Statistics in Medicine, 15: 2405{12.44. Rhodes P, Halloran ME, Longini IM. (1996) Counting process models for infectious disease data:distinguishing exposure to infection from susceptibility. J Roy Statist Soc B, 58:751{762.45. Longini, IM, Datta, S, and Halloran, ME. (1996) Measuring vaccine e cacy for both susceptibility toinfection and reduction in infectiousness for prophylactic HIV-1 vaccines. J AIDS and HR, 13:440{447.46. Bertolli J, Pangi C, Frerichs R, and Halloran ME. (1997) A case-control study of the e ectivenessof BCG vaccine for preventing leprosy in Yangon, Myanmar. International Journal of Epidemiology,26:888-896.47. Halloran ME, Struchiner CJ, and Longini, IM. (1997) Study designs for di erent e cacy and e ectivenessaspects of vaccination, American Journal of Epidemiology, 146:789-803.48. Datta, S, Halloran, ME and Longini, IM (1998) Augmented HIV vaccine trial designs for estimatingreduction in infectiousness and protective e cacy. Statistics in Medicine, 17:185-200.49. Longini IM, Sagatelian K, Rida WN, and Halloran ME. (1998) Optimal vaccine trial design whenestimating vaccine e cacy for susceptibility and infectiousness from multiple populations, Statisticsin Medicine, 17:1121-1136.50. Halloran, ME. (1998) Vaccine studies. Invited entry in Encyclopedia of Biostatistics, John Wiley andSons, Inc., pp 4687-94.51. Halloran, ME. (1998) Secondary attack rate. Invited entry in Encyclopedia of Biostatistics, John Wileyand Sons, Inc., pp 4025-29.52. Sun F, Ashley AE, Durham LK, Feingold E, Halloran ME, Manatunga AK, Sherman SL. (1998)Testing for contributions of mitochondrial DNA mutations to complex diseases, Genetic Epidemiology15:451-469.53. Durham, LK, Longini, IM, Halloran, ME, Clemens, JD, Nizam, A, Rao, M. (1998) Estimation ofvaccine e cacy in the presence of waning; Application to cholera vaccines, American Journal of Epidemiology,147:948-959.54. Golm, GT, Halloran, ME, and Longini, IM. (1998) Semiparametric models for mismeasured exposureinformation in vaccine trials, Statistics in Medicine, 17:2335-2352.55. Halloran, ME (1998) Statistical issues in HIV vaccine trial design, Journal of the Royal StatisticalSociety A, 161:265-272.56. Longini, IM, Hudgens, MG, Halloran, ME, Sagatelian, K. (1999) A Markov model for measuringvaccine e cacy for both susceptibility to infection and reduction in infectiousness for prophylacticHIV-1 vaccines, Statistics in Medicine, 18:53-68.957. Golm, GT, Halloran, ME and Longini, IM. (1999) Semiparametric methods for multiple exposuremismeasurement and a bivariate outcome in HIV vaccine trials, Biometrics, 55:94{101.58. Datta, S, Halloran, ME, and Longini, IM (1999) Randomization by individual or by household invaccine studies?, Biometrics, 55:792-8.59. Durham, LK, Halloran, ME, Longini, IM, Manatunga, AM (1999) Smoothing methods for exploringtime-dependent vaccine e ects Applied Statistics, 48(3):395-407.60. Halloran, ME, Longini, IM, Struchiner, CJ (1999) Design and interpretation of vaccine  eld studies.Epidemiologic Reviews, 21:73-88.61. Longini, IM and Hudgens, MG and Halloran, ME. (2001) Estimation of vaccine e cacy for bothsusceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines with partneraugmentation, in The Quantitative Evaluation of HIV Prevention Programs, editors Kaplan, E andBrookmeyer, R, Yale University Press, New Haven.62. Longini, IM, Halloran, ME, Nizam, A, Wol , M, Mendelman, PM, Fast, P, Belshe, RB. (2000) Estimationof the e cacy of live, attenuated inuenza vaccine from a two-year, multi-center vaccine trial:Implications for inuenza epidemic control, Vaccine 18:1902-1909.63. Hudgens MG, Longini IM, Halloran ME, Choopanya K, Vanichsen S, Kitayaporn D, Mastro TD, MockPA. (2001) Estimating the HIV transmission probability in injecting drug users in Thailand, AppliedStatistics, 50:1-14.64. Halloran, ME and Longini, IM. (2001) Use of validation sets for outcomes and exposure to infectionin vaccine  eld studies. American Journal of Epidemiology, 154:391{398.65. Halloran, ME. (2001) Invited Commentary on C.P. Farrington, M.N. Kanaan, N.J. Gay, Estimationof the basic reproduction number for infectious diseases from age-strati ed serological survey data.Applied Statistics, 50:287{288.66. Longini IM, Halloran ME, and Nizam, A. (2002) Model-based estimation of vaccine e ects from communityvaccine trials. Statistics in Medicine, 21:481-495.67. Hudgens MG, Longini, IM, Vanichsen S, Hu DJ, Kitayaporn D, Mock PA, Halloran ME, Satten GA,Choopanya K, Mastro TD (2002) Estimating HIV-1 subtype-speci c transmission probabilities amonginjection drug users in Bangkok, Thailand, American Journal of Epidemiology, 155:159-168.68. Halloran ME, Longini IM, Cowart DM, Nizam, A. (2002) Community trials of vaccination and theepidemic prevention potential, Vaccine, 20:3254-62.69. Halloran ME, Longini IM, Nizam A, and Yang Y. (2002) Containing bioterrorist smallpox, Science,298:1428-32.70. Halloran, ME, Pr eziosi, M-P, and Chu, H. (2003) Estimating vaccine e cacy from secondary attackrates, Journal of the American Statistical Association, 98:38{46.71. Pr eziosi, M-P and Halloran, ME. (2003) E ects of pertussis vaccination on transmission: vaccinee cacy for infectiousness, Vaccine, 21:1853{1861.1072. Halloran ME, Longini IM, Gaglani MJ, Piedra PA, Chu H, Herschler GB, Glezen WP. (2003) Estimatinge cacy of trivalent, cold-adapted, inuenza virus vaccine (CAIV-T) against inuenza A (H1N1)and B using surveillance cultures, American Journal of Epidemiology, 158:305-311.73. Pr eziosi, M-P and Halloran, ME. (2003) E ects of pertussis vaccination on disease: vaccine e cacyfor severity, Clinical Infectious Diseases, 37:772-779.74. Chu, H, Pr eziosi, M-P, and Halloran, ME (2004) Estimating heterogeneous transmission with multipleinfectives using MCMC methods, Statistics in Medicine, 23:35-49.75. Gaglani MJ, Piedra PA, Herschler GB, Gri th ME, Kozinetz CA, Riggs MW, Fewlass C, HalloranME, Longini IM, Glezen P. (2004) Direct e ectiveness of the intranaal, live-attenuated trivalent, coldadapted,inuenza Virus Vaccine (CAIV-T) against the 2000-2001 inuenza A (H1N1) and B epidemicin healthy children, Arch Pediatr Adolesc Med, 158:65{73.76. T.Cuenco K, Halloran ME, Louis-Charles J, and Lammie PJ. (2004) A family study of lymphedemaof the leg in a lymphatic  lariasis endemic area, American Journal of Tropical Medicine and Hygiene,70:180-184.77. T.Cuenco K, Halloran ME, and Lammie PJ. (2004) Assessment of families for excess risk of lymphedemaof the leg in a lymphatic endemic area, American Journal of Tropical Medicine and Hygiene,70:185-190.78. Longini IM, Halloran ME, Nizam A, and Yang Y. (2004) Containing pandemic inuenza with antivirals,American Journal of Epidemiology, 159:623-633.79. Chu, H and Halloran, ME. (2004) Estimating vaccine e cacy using auxilliary outcome data and asmall valdation set, Statistics in Medicine, 23:2697-2713.80. Chu, H and Halloran, ME. (2004) Bayesian estimation of vaccine e cacy, Clinical Trials, 1:306-314.81. Weycker D, Edelsberg J, Halloran ME, Longini IM, Nizam A, Ciuryla V, Oster G. (2005) Populationwidebene ts of routine vaccination of children against inuenza, Vaccine, 23:1284-1293.82. Longini, IM and Halloran, ME (2005) Strategy for distribution of inuenza vaccine to high-risk groupsand children, American Journal of Epidemiology, 161:303{306.83. Patel, R, Longini, IM, and Halloran ME (2005), Finding optimal vaccination strategies for pandemicinuenza using genetic algorithms, Journal of Theoretical Biology, 234:201-212.84. Halloran, ME and Lipsitch, M. (2005) Infectious Disease Modeling Contributions to the AmericanJournal of Epidemiology, American Journal of Epidemiology, 161:997-998.85. Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworaku W, Cummings DAT, Halloran, ME (2005)Containing pandemic inuenza at the source, Science, 309:1083{87.86. Halloran ME and Longini IM (2006) Community studies for vaccinating schoolchildren against in-uenza, Science, 311:615{616.87. Hudgens, MG and Halloran, ME. (2006) Causal vaccine e ects on binary post-infection outcomes,Journal of the American Statistical Association, 101:51{64.1188. Yang, Y, Longini, IM, and Halloran, ME (2006), Design and evaluation of prophylactic interventionsusing infectious disease incidence data from close contact groups, Applied Statistics, 55:317-330.89. Scharfstein DO, Halloran ME, Chu H, Daniels MJ. (2006) On estimation of vaccine e cacy usingvalidation samples with selection bias, Biostatistics 7:615-629.90. Struchiner CJ and Halloran ME (2007) Randomization and baseline transmission in vaccine  eldtrials, Epidemiology and Infection, 135:181{194, published online by Cambridge University Press July3, 2006.91. Longini IM, Halloran ME, Nizam A, Yang Y, Xu S, Burke DS, Cummings DAT, Epstein JM. (2007)Containing a bioterrorist smallpox attack, International Journal of Infectious Disease, 11:98{108.92. Halloran, ME. (2006) Invited Commentary: Challenges of using contact data to understand acuterespiratory disease transmission, American Journal of Epidemiology, 164:936{944.93. Halloran ME, Hayden FG, Yang Y, Longini, IM and Monto AS. (2007) Antiviral e ects on inuenzaviral transmission and pathogenicity: Observations from household-based trials, American Journal ofEpidemiology, 165:212{221.94. Halloran, ME, Piedra, PA, Longini, IM, Gaglani, MJ, Schmotzer, B, Fewlass, C, Herschler, GB,Glezen, WP. (2007) E cacy of Trivalent, Cold-Adapted, Inuenza Virus Vaccine Against Inuenza A(Fujian), a Drift Variant, during 2003-2004, Vaccine, 25:4038{4045.95. Fay MP, Halloran ME, Follmann DA. (2007) Accounting for variability in sample size estimation withapplications to nonadherence and estimation of variance and e ect size, Biometrics, 63:465{474.96. Yang Y, Longini, IM, Halloran, ME. (2007) A resampling-based test to detect person-to-person transmissionof infectious disease, Annals of Applied Statistics, 1:211{228.97. Yang, Y, Longini, IM, Halloran, ME (2007) A data-augmentation method for infectious disease incidencedata from close contact groups, Computational Statistics and Data Analysis, 51(12): 6582{6595.98. Yang, Y, Halloran, ME, Sugimoto, J, Longini, IM. (2007) Detecting human-to-human transmissionof Avian A(H5N1) inuenza, Emerging Infectious Diseases, September 2007. Available fromhttp://www.cdc.gov/EID/content/13/9/1348.htm.99. Wu, H, Yuan M, Kaech, S and Halloran ME (2007) A statistical analysis of memory CD8 T celldi erentiation: an application of a hierarchical state space model to short time course microarrayexperiments, Annals of Applied Statistics, 1:442-458.100. Hudgens, MG and Halloran, ME. (2008) Towards causal inference with interference, Journal of theAmerican Statistical Association, 103:832{842.101. Halloran ME, Ferguson NM, Eubank S, Longini IM, et al. (2008) Modeling targeted layered containmentof an inuenza pandemic in the United States, Proceedings of the National Academy of Sciences,105:4639{4644.102. Basta, NE, Halloran, ME, Matrajt, L, and Longini IM. (2008) Estimating inuenza vaccine e cacyfrom challenge study data, American Journal of Epidemiology, 168:1343{1352.12103. Yang, Y, Gilbert, P, Longini, IM, Halloran, ME. (2009) A Bayesian framework for estimating vaccinee cacy per infectious contact, Annals of Applied Statistics, 2:1409{1431.104. Yang, Y, Halloran, ME and Longini, IM. (2009) A Bayesian model for evaluating inuenza antivirale cacy from household studies with asymptomatic infections, Biostatistics, 10:364{373.105. Abu-Raddad, L, Sabatelli, L, Achterberg, JT, Sugimoto, JD, Longini, IM, Dye, C, Halloran ME. (2009)Epidemiological bene ts of more-e ective tuberculosis vaccines, drugs, and diagnostics, Proceedings ofthe National Academy of Sciences,106(33):13980{5, doi/10.1073/pnas.0901720106, early edition onlineAugust 3, 2009.106. Basta, NE, Chao, DL, Halloran, ME, Matrajt, L, and Longini, IM. (2009) Strategies for pandemic andseasonal inuenza vaccination of schoolchildren in the United States, American Journal of Epidemiology,170:671{678; doi:10.1093/aje/kwp201.107. Halloran, ME. (2009) On inuenza and school closings: Time for prospective studies, Invited commentary,Epidemiology, 20:793{795.108. Halloran, ME and Holmes, EC. (2009) Invited commentary: Evaluating vaccination programs usinggenetic sequence data, American Journal of Epidemiology, 170:1464{1466.109. Yang, Y, Sugimoto, JD, Halloran, ME, Basta , NE, Chao, DL, Matrajt, L, Potter, G, Kenah, E,Longini, IM. (2009) The transmissibility and control of novel inuenza A (H1N1) virus, Science,326:729{733.110. Chao, DL, Halloran, ME, Obenchain, VJ, and Longini, IM (2010) FluTE, a publicly available stochasticinuenza epidemic simulation model, PLoS Computational Biology 6(1): e1000656.doi:10.1371/journal.pcbi.1000656.111. Yang, Y, Halloran, ME, Daniels, MJ, Longini, IM, Cummings, DAT, and Burke, DS (2010) Modelingcompeting infectious pathogens from a Bayesian perspective: Application to inuenza studies withincomplete laboratory results, Journal of the American Statistical Association, in press.112. Chao, DL, Halloran, ME, Longini, IM (2010) School opening dates predict pandemic inuenza A(H1N1) epidemics in the USA, Journal of Infectious Diseases, in press.Submitted papers1. Hertz, T, Jojic, N, Mallal, S, Phillips, E, Halloran, ME and Corey, L (2010) Antigenic variability ofhuman HLA types to the novel swine-origin inuenza A (H1N1) virus - A computational analysis,submitted.Other publications1. Denker C, Doughten D, Halloran ME et al. (1979)  Uber die beruiche Erfahrung von weiblichen Arzten: Ergebnisse einer Befragung, (Concerning the Experiences of Woman Doctors in their Careersand Personal Lives: Results of an Investigation), Department of Social Medicine, Freie Universitat,Berlin-Dahlem, Germany.2. Shapira A, Beales PF, Halloran ME. (1993) Living with drug resistance to malaria. ParasitologyToday, 9:168-174.133. Halloran, ME and Struchiner CJ. (1995) Vaccine e ects: Changes in susceptibility, infectiousness,contacts, direct and indirect e ects. in Proceedings of the III Brazilian/ II Ibero American/ LatinAmerican Congress on Epidemiology, April, 24{28, 1995. (Biostatistics Technical Report 95{9).4. Halloran, ME. (1995) The potential outcome approach to cause. Invited Paper at the Interface Conference,Pittsburgh, June 1995, Biostatistics Technical Report 95{3.5. Zanetta DMT, Halloran ME and Hawley, W. (1995) Analysis of repeated measurement data: anexample. Technical Report 95{6, Department of Biostatistics, Emory University.6. Dunson, D and Halloran ME. (1996) Estimating transmission blocking e cacy of malaria vaccines,Technical Report 96{16.7. Halloran ME, Anderson RM, Azevedo-Neto RS, Bellini WJ, Branch O, Burke MA, Compans R, Day K,Gooding L, Gupta S, Katz J, Kew O, Keyserling H, Krause R, Lal AA, Massad E, McLean AR, RosaP, Rota P, Wiener P, Wynn SG, Zanetta DMT. (1998) Population Biology, Evolution and Immunologyof Vaccination and Vaccination Programs. American Journal of Medical Sciences, 315:76-86.8. Golm, GT, Halloran, ME and Longini, IM. (1999) Validation sets for exposure to infection in HIVvaccine trials. Proceedings of the Epidemiology Section of the American Statistical Association, Dallas,August 1998.9. Golm, GT and Halloran, ME (1998) Optimal sampling fractions and the mean score method for vaccinetrials with mismeasured exposure information, Technical Report, Department of Biostatistics, Emory.10. Halloran, ME. (2004) Statistics, biostatistics, and infectious disease. Amstat News, Invited President'sCorner article, June, Issue 324, pp 2-3.Books1. Halloran, ME, Longini, IM, and Struchiner, CJ (2009) Design and Analysis of Vaccine Studies,Springer Verlag.Edited Collections1. Statistics in Genetics, (1999) eds. Halloran ME and Geisser, S. (IMA volumes in mathematics and itsapplications; vol.112). Springer Verlag, New York.2. Statistics in Epidemiology, Environmental Health and Clinical Trials, (1999) eds. Halloran ME andBerry, D. (IMA volumes in mathematics and its applications; vol. 116). Springer Verlag, New York.Book Chapters1. Halloran ME. (1993) Concept and estimation of attributable risks in HIV epidemiologic research, inModels and Methods of Epidemiologic Research on HIV Infection, ed. Alfredo Nicolosi, Raven Press.2. Halloran ME. (1996) Epidemiologic e ects of varicella vaccination, in Infectious Disease Clinics ofNorth America, ed. RW Ellis and CJ White. W.B. Saunders Co. 10:631{655.3. Halloran ME. (1998) Concepts of Infectious Disease Epidemiology, in Modern Epidemiology, ed. RothmanK and Greenland S, 2nd edition, Lippincott Raven Publishers.144. Halloran ME. (2001) Concepts of Transmission and Dynamics, in Epidemiologic Methods for the Studyof Infectious Diseases, ed. Thomas, J.C., Weber, D.J., Oxford University Press, Oxford, pp. 56-85.5. Halloran ME. (2001) Overview of Study Design, Epidemiologic Methods for the Study of InfectiousDiseases, ed. Thomas, J.C., Weber, D.J., Oxford University Press, Oxford, pp 86-115.Book Reviews1. Infectious Diseases of Humans, by R.M. Anderson and R.M. May. in Trends in Microbiology, 1994.2. Bayesian Data Analysis, by A. Gelman, J. Carlin, H. Stern, D. Rubin, andBayesian and Empirical Bayes Methods for Data Analysis, by B. Carlin and T.A. Louis, (1997) Journalof the American Statistical Association, 92:1640-1642.Abstracts1. T.Cuenco K, Halloran ME, Addiss DG, Streit TG, Lammie PJ. Familial clustering of lymphedemaof the leg in a lymphatic  lariasis-endemic area. Presented at the Meeting of the Society of TropicalMedical and Hygiene, Houston, November 2000.Emory University School of Public Health: committees1990{91 Chair, Ad hoc International Health Evaluation Committee1991 Member, Search Committee for Director of the Center of International Health1991{92 Member, Accreditation self-study committee for research1991{92 Member, Search committee for two Biostatistics Associate Faculty1992{93 Chair, Search committee for Infectious Disease Epidemiologist,Center for International Health1992{93 Chair, Search committee for Director of the Division of Biostatistics1992{93 Chair, Search committee for PhD Faculty (junior and senior), Division of Biostatistics1993 Member, Search committee for Infectious Disease Epidemiologist,Center for International Health1993 Member, Search committee for Director of the Division of Biostatistics1994{97 Editor, Biostatistics Technical Report Series1994{95 Chair, Biostatistics PhD Curriculum Revision1995{96 Chair, Biostatistics PhD Review1996 Member, School Accreditation Committee for Research1997 Member, School Research Strategic Planning Committee1996{2003 Member, Biostatistics Computing Committee1996{1999 Member, School Appointment, Promotions, and Tenure Committee1999{2002 Member, School Appointment, Promotions, and Tenure Professor Committee1999{2000 Chair, Search committee for tenure-track faculty, Biostatistics2000 Chair, Junior faculty review, Biostatistics2002 Chair, Assistant and Associate Professor review, Biostatistics2001{2002 Member, Search Committee for Chair of Epidemiology2002{2004 Member, Search Committee for Chair of Biostatistics2003{2005 Chair, Biostatistics Computing Advisory Committee2003{2004 Chair, Biostatistics Ad hoc Committee on Student Financial Support2004 Chair, Biostatistics Strategic Planning Retreat15Emory University School of Public Health: other service1990 Author, Perspectives for Epidemiology and Biostatistics in the School of PublicHealth, Discussion paper for Departmental Faculty Retreat, June 1990.1992 Advisor, Survey on Gender Issues1992 Co-organizor, Faculty Discussion on Gender Issues1991 Co-initiator and co-organizor, Meetings of the women faculty on gender issues1992 Coordinator, Biostatistics short course by Martin A. Tanner at Emory, 9/14{16.Emory University service1991{94 Member, Advisory Committee, Institute for Women's Studies1990{91 Member, Emory /Carter Center Task Force1991 Initiator and organizor, Mini-conference on perspectives for research on vector-bornediseases at Emory, with Jose M.C. Ribeiro, January, 1991.1990{92 Initiator of invitation and organizor for visiting exhibit: The Value of the Human Being:Medicine in Germany 1915-1945.1992{93 Member, Search committee for two population biologists, Department of Biology1993{96 Member, New PhD Program development of Population Biology, Ecology,and Evolution, Graduate Division of Biological and Biomedical Sciences1995 Co-organizor, Emory Workshop on Population Biology, Evolution and Control ofInfectious Diseases, February 22{23, 1995.1996{97 Chair, Provost's University Committee to Review Statistics at Emory1998{2003 Executive Committee, Atlanta Area Vaccine Dinner Club1999{2003 Steering Committee to form Center for Disease Ecology2001{2002 Member, Search Committee Georgia Research Alliance Chair, Quantitative Genetics2002{2003 Emory Representative to Georgia Research Alliance Bioinformatics Cluster2001{2004 Emory representative to American Association of University Women (AAUW)University of Washington service2006-present Biostatistics Faculty Development CommitteeActive and continued grants4/92-6/15 Principal investigator, National Institutes of Health, R01 AI032042:Methods for evaluating vaccine e cacyDirect costs (10{15):  $1,700,000. Indirect costs:  $1,200,000.Direct costs (05{10):  $1,100,000. Indirect costs:  $710,000.Direct costs (99{05): $897,584. Indirect costs: $471,288.Direct costs (95{99): $690,479. Indirect costs: $393,573.Direct costs (92{95): $298,162. Indirect costs: $161,847.5/09-4/14 (MPI) Principal investigator, National Institutes of Health, U01 GM070749:Containing Bioterrorist and Emerging Infectious DiseasesDirect costs (09{14):  $2,700,000. Indirect costs:  $.12/09-11/13 Principal investigator, Subcontract, National Institutes of Health, R01 AI085073:Causal Inference for Infectious Disease Studies16P.I. Michael Hudgens, UNC Chapel HillDirect costs (subcontract) (09{13): $430,000. Indirect costs: $276,000.3/10-2/14 Director, National Institutes of Health, R25 GM089694:Summer Institute in Statistics and Modeling in Infectious DiseasesBiostatistics, University of WashingtonDirect costs (10{14): $720,000. Indirect costs: $37,000.Former grants and contracts3/07-6/09 Principal investigator, Bill and Melinda Gates Foundation, Contract 5485:Evaluating the BMGF Portfolio of New TB Drugs, Diagnostics and VaccinesDirect costs (07{09): $509,663. Indirect costs: $201,465.7/05-6/10 Program Director, National Institutes of Health NIGMS T32 GM074909 (left 12/05):Biostatistics in Genetics, Immunology, and NeuroimagingDirect costs (05-06): $179,684. Indirect costs: $7,447.4/05{11/05 Principal investigator, National Institutes of Health, R56 AI32042-A1:Methods for evaluating vaccine e cacyDirect costs (05{06): $267,304. Indirect costs: $123,233.10/02-12/05 Core Director (Biostatistics), National Institutes of HealthCFAR (PI Curran)Direct costs (year): $97,650. Indirect costs: $.6/05-5/06 Awardee, Emory University, University Teaching Fund AwardCourse on Causal Inference, Direct costs (year): $5,000.10/92-8/03 Program Director, National Institutes of Health T32 AI07442:Statistical and Clinical Research Training on AIDSDirect costs (97{03): $429,712. Indirect costs: $34,377.Direct costs (92{97): $334,635. Indirect costs: $26,770.10/03-9/04 Principal investigator, National Institutes of Health, 263-MD-306089:Analytic methods for determining smallpox control in response to abioterrorist attackDirect costs: $71,533. Indirect costs: $26,467.2/03-7/03 Principal investigator, National Institutes of Health, 263-MD-306089:Analytic methods for determining smallpox control in reponse to abioterrorist attackDirect costs: $71,533. Indirect costs: $26,467.12/01-5/02 University Teaching Fund Award, Emory UniversityAnalysis of Microarray DataDirect costs: $8,000.9/01-8/02 IPA Agreement, Centers for Disease Control, 01IP09659Evaluating Prophylactic Antivirals against InuenzaDirect costs: $43,645.7/00-10/01 Principal investigator, National Institutes of Health, R13 CA91646:Conference on Causation, Statistics, and ApplicationsDirect costs: $99,000.4/97-3/01 Principal investigator, National Institutes of Health, R01 AI40846:17Design and analysis of HIV vaccine trialsDirect costs (97{01): $370,000. Indirect costs: $182,000.4/91-3/97 Principal Investigator, National Institutes of Health FIRST Award R29 AI31057:Study designs for malaria and other vector-borne diseaseDirect costs (92{97): $336,087. Indirect costs: $158,834.7/94-7/96 Principal Investigator, National Science Foundation Career Advancement Award DMS-9410138:Foundations and Methods of InferenceDirect costs: $27,500. Indirect costs: $2,500.1997 University Teaching Fund Award, Emory UniversityDeveloping a course in Statistical ComputingDirect costs: $4,900.1997-8 University Research Fund Award, Emory UniversityEstimating the Relation of Exposure to Malaria Infection to ImmunityDirect costs: $4,811.11/91-3/92 Principal Investigator. Centers for Disease Control Contract 308MIM92Application of Mathematical Modeling of a Varicella Vaccination ProgramDirect costs: $7,028. Indirect costs: $2,811.9/90-2/91 Principal Investigator. Centers for Disease Control Contract 434MIM90Mathematical Modeling of a Varicella Vaccination ProgramDirect costs: $16,818. Indirect costs: $1,682.July 6, 201018